App-Quantinova.ai

A phase II study of eribulin in patients with HER2-negative, metastatic breast cancer: Evaluation of efficacy, toxicity, and patient-reported outcomes.

Otto Metzger-Filho - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Eribulin

Trends in treatment patterns and outcomes for DCIS patients: A SEER population-based analysis.

Mathias Worni - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Late axillary recurrence after negative SLNB.

Cindy Brown Matsen - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype.

Sayaka Kuba - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Accuracy of ultrasound during neoadjuvant therapy for breast cancer to predict pathologic response.

Michael Luke Marinovich - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A multicenter prospective study of image-guided radiofrequency ablation for small breast carcinomas.

Takayuki Kinoshita - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

What-s in a name: Describing ductal carcinoma in situ (DCIS).

Lesley Fallowfield - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Cup size and nipple-sparing mastectomy.

Sunny D. Mitchell - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Predictive biomarkers of invasive carcinoma on excision in patients with a diagnosis of ductal carcinoma in situ of the breast by needle biopsy.

Miki Mori - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer.

Kenji Tamura - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Cyclophosphamide

Uncovering the dynamic relationship between Ki-67 and mitotic indices in breast cancer.

Guilherme Henrique Cantuaria - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The relationship between body mass index, diabetes, and triple-negative breast cancer prognosis.

Jose Maria Pacheco - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Evaluation of lymphocyte infiltrate composition in triple-negative mammary carcinomas and its association with clinical-pathologic and demographic data.

Geraldine Eltz Lima - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

SGN-LIV1A, an antibody-drug conjugate (ADC), in patients with LIV-1positive breast cancer.

Ana Kostic - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

SGN-LIV1A

Analysis of somatic copy number alterations in pediatric solid tumors using array comparative genomic hybridization.

Alanna Church - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Evaluation of breast cancer incidence in Lynch syndrome patients by MMR gene.

Jamie Willmott - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The clinical experience: Hereditary cancer testing by a 25-gene panel.

Elias Obeid - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Are immunohistochemical (IHC)/microsatellite instability (MSI) testing necessary as part of Lynch syndrome work-up in the era of multiplex genetic testing?

Ahmad Fitri Idris - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Classification of somatic variants in solid tumors detected by next-generation sequencing (NGS) and the need for clinical guidelines.

Antonios Papanicolau-Sengos - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

BRCAPRO 6.0 model validation in male patients presenting for BRCA testing.

Zahi Ibrahim Mitri - American Society of Clinical Oncology (ASCO) , 2014

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts